Exondys 51 Archives -

Shares in Sarepta came under pressure after the biotech said it had temporarily halted a clinical trial of

Sarepta shares yo-yo as FDA places hold on Duchenne trial

https://pharmaphorum.com/news/sarepta-shares-yo-yo-as-fda-places-hold-on-duchenne-trial/

The FDA has rejected Sarepta Therapeutics’ new Duchenne muscular dystrophy (DMD) Vyondys 53 due to concerns about potential

FDA says no to Sarepta’s golodirsen, blocking bid to expand its Duchenne stable

https://pharmaphorum.com/news/fda-says-no-to-sarepta-blocking-bid-to-expand-its-duchenne-stable/

Controversy has dogged Sarepta’s Duchenne muscular dystrophy therapy Exondys 51 since its approval, and it’s not out of

ICER posts damning report on Sarepta’s Duchenne drug Exondys 51

https://pharmaphorum.com/news/icer-posts-damning-report-on-sareptas-duchenne-drug-exondys-51/

Exondys 51